Cethromycin is in late-stage evaluation as a treatment for respiratory tract infections.
The NIAID plans to evaluate Advanced Life Sciences Holdings’ antibiotic, cethromycin, as a treatment for anthrax and in other high-priority biodefense areas. The drug currently is in Phase III development for the treatment of community-acquired pneumonia and other respiratory tract infections.
“We are very excited about our partnership with the NIAID as it allows us to leverage the financial and scientific resources of the U.S. government’s premier research institute to develop cethromycin as a broad spectrum medical countermeasure,” says Michael T. Flavin, Ph.D., CEO. “This partnership with NIAID will expand the data on cethromycin as a biodefense application, and we expect the results to strengthen our efforts in positioning cethromycin for purchase by the U.S. government.”
This collaboration is part of the U.S. government’s effort to accelerate the R&D of biodefense agents under Project BioShield.